<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38612">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02047422</url>
  </required_header>
  <id_info>
    <org_study_id>4-2013-0808</org_study_id>
    <nct_id>NCT02047422</nct_id>
  </id_info>
  <brief_title>A Prospective, Single-center, Randomized, Controlled, Open-label, Pilot Study to Compare the Effectiveness and Safety of DIuretics Add-On Strategy in Acute Decompensated Heart Failure Patients (DIOS II)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effectiveness and safety of diuretics add-on strategy in chronic heart
      failure patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>urine output change</measure>
    <time_frame>from admission to Hospital Day (HOD)#4</time_frame>
    <safety_issue>No</safety_issue>
    <description>efficacy of diuretics add-on therapy, urine output change</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum creatinine change</measure>
    <time_frame>from admission to HOD#4</time_frame>
    <safety_issue>No</safety_issue>
    <description>safety of diuretics add-on therapy, serum creatinine change</description>
  </secondary_outcome>
  <other_outcome>
    <measure>body weight change</measure>
    <time_frame>from admission to HOD#4</time_frame>
    <safety_issue>No</safety_issue>
    <description>body weight change, symptoms &amp; signs change</description>
  </other_outcome>
  <other_outcome>
    <measure>urine creatinine change</measure>
    <time_frame>from admission to HOD#4</time_frame>
    <safety_issue>No</safety_issue>
    <description>urine creatinine change, serum &amp; urine electrolyte change, biomarkers change</description>
  </other_outcome>
  <other_outcome>
    <measure>clinical outcomes</measure>
    <time_frame>at 90 days after discharge</time_frame>
    <safety_issue>No</safety_issue>
    <description>clinical outcomes ( all-cause mortality, all-cause rehospitalization, start of renal replacement therapy)</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>Add furosemide/no spironolactone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Add metolazone/no spironolactone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Add furosemid/spironolactone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Add metolazone/spironolactone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>furosemide (doubling previous furosemide dose)</description>
    <arm_group_label>Add furosemide/no spironolactone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metolazone</intervention_name>
    <description>metolazone (add 2.5mg qod)</description>
    <arm_group_label>Add metolazone/no spironolactone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>furosemid/spironolactone</intervention_name>
    <description>spironolactone (doubling previous spironoalctone dose or add 12.5mg BID if previous non-user)</description>
    <arm_group_label>Add furosemid/spironolactone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metolazone/spironolactone</intervention_name>
    <description>no spironolactone (maintaining previous spironolactone dose or not add spironolactone if previous non-user)</description>
    <arm_group_label>Add metolazone/spironolactone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. dyspnea at rest or minimal activity

          2. tachypnea (respiratory rate &gt; 20/min) or rales or pulmonary edema on chest X-ray

        Exclusion Criteria:

          1. hospitalization for acute heart failure decompensation

          2. cardiogenic shock (Systolic Blood Pressure &lt; 80mmHg)

          3. Need or plan for renal replacement therapy (dialysis, kidney transplant)

          4. serum creatine level &gt; 2.5mg/dl

          5. serum potassium (K+) &gt; 5.5mg/dl

          6. Age &gt; 80 years old or poor compliance patients

          7. allergy, adverse drug reaction, hypersensitivity to any kinds of diuretics

          8. life expectancy &lt; 6 months (e.g. metastatic malignancy, liver cirrhosis)

          9. pregnancy or women at age of childbearing potential
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Seok-Min Kang, MD</last_name>
    <phone>82-2-2228-8450</phone>
    <email>smkang@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seok-Min Kang, MD</last_name>
      <phone>82-2-2228-8450</phone>
      <email>smkang@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 26, 2014</lastchanged_date>
  <firstreceived_date>January 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure, diuretics, kidney, glomerular filtration rate</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Metolazone</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
